Tourette Syndrome - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 70 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Tourette Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Tourette Syndrome - Pipeline Review, H2 2014', provides an overview of the Tourette Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tourette Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Tourette Syndrome - Overview 8
Pipeline Products for Tourette Syndrome - Comparative Analysis 9
Tourette Syndrome - Therapeutics under Development by Companies 10
Tourette Syndrome - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Tourette Syndrome - Products under Development by Companies 16
Tourette Syndrome - Companies Involved in Therapeutics Development 17
AstraZeneca PLC 17
Neurocrine Biosciences, Inc. 18
Catalyst Pharmaceutical Partners, Inc. 19
Auspex Pharmaceuticals, Inc. 20
Edison Pharmaceuticals, Inc. 21
Otsuka Holdings Co., Ltd. 22
Reviva Pharmaceuticals Inc. 23
Psyadon Pharmaceuticals, Inc. 24
Tourette Syndrome - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 33
aripiprazole - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ecopipam hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AZD-5213 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
vigabatrin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
vatiquinone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
dutetrabenazine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
valbenazine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
RP-5063 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Tourette Syndrome - Recent Pipeline Updates 48
Tourette Syndrome - Dormant Projects 61
Tourette Syndrome - Discontinued Products 62
Tourette Syndrome - Product Development Milestones 63
Featured News & Press Releases 63
May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome in Children Ages 7-17 63
Sep 24, 2012: Catalyst Pharma Announces Initiation Of CPP-109 Investigator-Sponsored Study In Patients With Treatment Refractory Tourette's Disorder 63
Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome 64
Feb 09, 2012: Catalyst Files Provisional Patent Application For GABA Aminotransferase Inhibitor CPP-115 In Treatment Of Tourette Syndrome 65
Feb 09, 2012: Catalyst Files US Provisional Patent Application For GABA Aminotransferase Inhibitor CPP-109 In Treatment Of Tourette Syndrome 66
Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854 66
May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment 67
Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation 67
Nov 16, 2010: Otsuka Prevails In US Abilify Patent Litigation 68
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Tables
Number of Products under Development for Tourette Syndrome, H2 2014 8
Number of Products under Development for Tourette Syndrome - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Comparative Analysis by Unknown Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Tourette Syndrome - Pipeline by AstraZeneca PLC, H2 2014 17
Tourette Syndrome - Pipeline by Neurocrine Biosciences, Inc., H2 2014 18
Tourette Syndrome - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2014 19
Tourette Syndrome - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 20
Tourette Syndrome - Pipeline by Edison Pharmaceuticals, Inc., H2 2014 21
Tourette Syndrome - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 22
Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 23
Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals, Inc., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 32
Tourette Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 48
Tourette Syndrome - Dormant Projects, H2 2014 61
Tourette Syndrome - Discontinued Products, H2 2014 62